Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Lambda interferon in resisting human immunodeficiency virus

A technology of human immunodeficiency and interferon, which is applied in the application field of a new type of interferon - interferon λ in anti-human immunodeficiency virus

Inactive Publication Date: 2009-11-11
WUHAN UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the anti-HIV effect of IFN-λ has not been reported by scientific and technological search

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Lambda interferon in resisting human immunodeficiency virus
  • Application of Lambda interferon in resisting human immunodeficiency virus
  • Application of Lambda interferon in resisting human immunodeficiency virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Toxic effect of IFN-λ on human macrophages

[0022] Differentiated mature human macrophages were added with different concentrations of IFN-λ1 / λ2 and cultured for 72 hours. The cytotoxic effect of IFN-λ1 / λ2 was detected by MTS method. The results showed that the concentration of IFN-λ1 / λ2 ranged from 1ng / ml to 1000ng / ml is less than 10% for human macrophage toxicity, and there is no significant difference in statistical analysis, so it can be considered that IFN-λ1 / λ2 has no toxicity to human macrophages ( figure 1) .

Embodiment 2

[0023] Embodiment 2: IFN-λ anti-human immunodeficiency virus (HIV-1) infection in vitro

[0024] IFN-λ1 / λ2 (100ng / ml) pretreated differentiated mature human macrophages for 24 hours, HIV-1R5 strains Bal, Jago and JRFL (P24 protein content were all 30ng / 10 6 cells) were infected for 2 hours, washed three times with DMEM medium, then added DMEM (V / V) medium containing 10% fetal bovine serum, 37 ° C, 5% CO 2 (V / V) culture; on the 8th day after infection, observed under the light microscope, the macrophages in the HIV-1 infection group presented a typical multinucleated giant cell morphology, and the multinucleated giant cells in the IFN-λ treatment group were significantly less than the virus control group ( figure 2) .

[0025] Cell supernatants were collected on day 8 post-infection and isotopic 32 P-labeled HIV reverse transcriptase method and ELISA method were used to detect HIV-1 viral reverse transcriptase (RT) and P24 protein. The content of P24 was significantly lower...

Embodiment 3

[0026] Example 3: IFN-λ anti-HIV-1 infection in vitro has a time effect:

[0027] IFN-λ1 / λ2 (100ng / ml) pretreated differentiated mature human macrophages for 24 hours, infected with HIV-1 Bal strain for 2 hours, washed three times with DMEM medium, and then added DMEM containing 10% fetal bovine serum (V / V) Medium, 37°C, 5% CO 2 (V / V) culture; cell supernatants were collected on the 4th day, 8th day and 12th day of infection respectively, and isotope was applied 32 P marker HIV reverse transcriptase method to detect RT. The results showed that on the 8th day after infection, the effect of inhibiting HIV-1 infection was obvious ( Figure 4, P Figure 4, P<0.05). It shows that IFN-λ inhibits the replication and infection of HIV-1 in human macrophages and presents a time relationship.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Lambda interferon in resisting human immunodeficiency virus. IFN-Lambda resisting HIV infection can inhibit the infection and replication of HIV-1 in human macrophage, which is presented by the following processes: (1) IFN-Lambda1 / Lambda2 differentiates mature human macrophage through pretreatment, then HIV-1R5 type strain respectively infects the cells, a DMEM culture medium is used for washing and then a DMEM culture medium containing 10 percent of fetal calf serum is added for culture; and (2) after infection, the formed multinucleate giant cells of IFN-Lambda treatment group are rather less than those of a virus contrast group, and the HIV-1 reverse transcriptase and envelope protein P24 in culture supernatant fluid of the IFN-Lambda treatment group are detected to be rather less than that of the virus contrast group. After infection, the HIV-1RT in the culture supernatant fluid is respectively detected. The effect of inhibiting the HIV-1 is obvious after infection. The IFN-Lambda treatment group has obvious time and dose-effect relationship in inhibiting the activity of HIV-1RT after infection. The function of IFN-Lambda in resisting the HIV-1 is similar to that of other interferons and has the antivirus effect. The IFN-Lambda shows obvious effect of inhibiting the replication of virus as regards to the human macrophage before, in and after the infection of the HIV-1 virus.

Description

technical field [0001] The invention belongs to the field of antiviral drugs, in particular, the invention relates to the application of a new type of interferon-λ interferon (interferon lambda, IFN-λ) in anti-human immunodeficiency virus (HIV-1). Background technique [0002] Human immunodeficiency virus (HIV) is the cause of acquired immunodeficiency syndrome (AIDS). Patients are characterized by CD4+T cell reduction, accompanied by repeated opportunistic infections, malignant tumors, and degeneration of the central nervous system. During the twenty-seven years since the HIV / AIDS epidemic broke out, about 65 million people worldwide were infected with HIV, and 25 million of them died. If nothing is done to combat the HIV / AIDS epidemic, it will turn into a historic catastrophe with an estimated millions of new infections by the end of this decade. [0003] Because HIV mainly invades CD4+ T cells and mononuclear phagocytes, and relies on a variety of active molecules in inf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/21A61P31/18
Inventor 霍文哲侯炜王旭杨占秋
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com